摘要
目的探讨糖蛋白抗原125(CA125)、人附睾蛋白4(HE4)、血清淀粉样蛋白A(SAA)和基质金属蛋白酶-1(MMP-1)在卵巢癌诊断和预后评估中的临床价值。方法收集卵巢癌患者94例作为病例组,同期收取卵巢良性疾病患者106例作为对照组。结果与对照组相比,病例组血清CA125、HE4、SAA、MMP-1水平均增高(P<0.05)。与低CA125组和低MMP-1组相比,高CA125组、高MMP-1组生存时间显著缩短(log-rank P=0.011,log-rank P=0.004)。结论血清CA125、HE4、SAA和MMP-1在卵巢癌诊断以及预后评估中具有重要的临床意义。
Objective To explore the clinical value of glycoprotein antigen 125(CA125),human epididymal protein 4(HE4),serum amyloid protein A(SAA)and matrix metalloproteinase-1(MMP-1)in the diagnosis and prognosis evaluation of ovarian cancer.Methods 94 cases of ovarian cancer were the case group,and 106 patients with ovarian benign disease were the control group.Results Compared with the control group,serum LEVELS of CA125,HE4,SAA and MMP-1 were all increased in the case group(P<0.05).Compared with the low CA125 group and the low MMP-1 group,the survival time of patients in the high CA125 group and the high CA125 group was significantly reduced(log-rank P=0.011,log-rank P=0.004).Conclusion The diagnostic value of serum CA125,HE4,SAA and MMP-1 in ovarian cancer and serum CA125 and MMP-1 in ovarian cancer patients prognosis evaluation have great clinical significance.
作者
刘博
魏丽
索美芳
LIU Bo;WEI Li;SUO Meifang(Nanyang Central Hospita,Nanyang,473000)
出处
《实用癌症杂志》
2022年第3期380-383,共4页
The Practical Journal of Cancer
基金
河南省医学科技攻关计划联合共建项目(编号:LHGJ20191364)。
